Advertisement
Advertisement
U.S. markets close in 1 hour 25 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Silk Road Medical, Inc (SILK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
47.62-0.76 (-1.57%)
As of 02:33PM EDT. Market open.
Advertisement
Full screen
Loading interactive chart...
  • Benzinga

    Silk Road Medical's Q2 Margins Hit By Manufacturing Expansion Costs

    Silk Road Medical Inc (NASDAQ: SILK) posted Q2 revenue of $33.2 million, an increase of 25% Y/Y, driven primarily by increased TCAR adoption, beating the consensus of $31.16 million. "We expanded our FDA label and Medicare coverage for the use of TCAR in standard surgical risk patients, formally initiated our ROADSTER 3 post approval study, and secured access to a $250 million debt facility," said Erica Rogers, CEO "We also gained meaningful market share through strong physician utilization as w

  • Zacks

    Silk Road Medical (SILK) Reports Q2 Loss, Tops Revenue Estimates

    Silk Road Medical (SILK) delivered earnings and revenue surprises of 6.38% and 6.91%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Silk Road Medical Reports Second Quarter 2022 Financial Results

    SUNNYVALE, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended June 30, 2022. “We achieved several important milestones in the second quarter. We expanded our FDA label and Medicare coverage for the use of TCAR in standard surgical risk patients, formally initiated our ROADSTER 3 post approval study, and secured access to a $250 mi

Advertisement
Advertisement